CL2019001369A1 - Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo. - Google Patents
Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo.Info
- Publication number
- CL2019001369A1 CL2019001369A1 CL2019001369A CL2019001369A CL2019001369A1 CL 2019001369 A1 CL2019001369 A1 CL 2019001369A1 CL 2019001369 A CL2019001369 A CL 2019001369A CL 2019001369 A CL2019001369 A CL 2019001369A CL 2019001369 A1 CL2019001369 A1 CL 2019001369A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical composition
- preventing
- producing
- crystalline polymorph
- breast cancer
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- UYVQXFOBKTWZCW-UHFFFAOYSA-N tetraarsenic Chemical compound [As]12[As]3[As]1[As]32 UYVQXFOBKTWZCW-UHFFFAOYSA-N 0.000 title abstract 2
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/285—Arsenic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G28/00—Compounds of arsenic
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G28/00—Compounds of arsenic
- C01G28/005—Oxides; Hydroxides; Oxyacids
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
- C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
- C01P2002/77—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by unit-cell parameters, atom positions or structure diagrams
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/80—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70
- C01P2002/88—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70 by thermal analysis data, e.g. TGA, DTA, DSC
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/80—Compositional purity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
Abstract
COMPOSICIÓN FARMACÉUTICA QUE CONTIENE HEXÓXIDO DE TETRAARSÉNICO (AS4O6) COMO INGREDIENTE ACTIVO EN UN 99% EN PESO O MÁS DEL POLIMORFO CRISTALINO A; METODO DE PREPARACION
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160155228A KR101834366B1 (ko) | 2016-11-21 | 2016-11-21 | 육산화사비소의 결정다형을 포함하는 유방암 예방 또는 치료용 약학 조성물 및 이의 제조방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019001369A1 true CL2019001369A1 (es) | 2020-02-21 |
Family
ID=61726934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019001369A CL2019001369A1 (es) | 2016-11-21 | 2019-05-20 | Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo. |
Country Status (16)
Country | Link |
---|---|
US (1) | US10525079B2 (es) |
EP (1) | EP3542803B1 (es) |
JP (1) | JP6824432B2 (es) |
KR (1) | KR101834366B1 (es) |
CN (2) | CN116440161A (es) |
AU (1) | AU2017360701B2 (es) |
BR (1) | BR112019009483A2 (es) |
CA (1) | CA3043153C (es) |
CL (1) | CL2019001369A1 (es) |
IL (1) | IL266706B (es) |
MX (1) | MX2019005736A (es) |
MY (1) | MY197198A (es) |
PH (1) | PH12019501119A1 (es) |
SA (1) | SA519401785B1 (es) |
WO (1) | WO2018093215A1 (es) |
ZA (1) | ZA201902612B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3176170T (pt) | 2012-06-13 | 2019-02-05 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
SG10201708520YA (en) | 2013-04-19 | 2017-12-28 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
TWI712601B (zh) | 2015-02-20 | 2020-12-11 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
KR101844049B1 (ko) * | 2016-12-05 | 2018-03-30 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물 |
KR101844050B1 (ko) * | 2016-12-09 | 2018-05-14 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3157361A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤としての三環式複素環 |
EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100272835B1 (ko) * | 1998-05-08 | 2000-11-15 | 배일주 | 천연 화학물질 육산화사비소의 신규한 항종양 치료제로서의 용도 및 그 약학적 조성물 |
US7261906B2 (en) * | 1998-05-08 | 2007-08-28 | Ill-Ju Bae | Anti-cancer therapy agent of arsenic hexoxide (As4O6) of a natural chemical substance and its pharmaceutical composition |
KR100399657B1 (ko) * | 2000-06-29 | 2003-09-29 | 배일주 | 혈관신생 억제제 |
CN1471925A (zh) * | 2002-08-02 | 2004-02-04 | 丛繁滋 | 更适于硬质肿瘤直接给药的含砷组合物、制剂及制备方法 |
KR100483195B1 (ko) | 2002-08-12 | 2005-04-14 | 배일주 | 육산화사비소를 유효성분으로 함유하는 사상충증예방·치료용 약제학적 조성물 |
KR101572529B1 (ko) | 2008-11-14 | 2015-11-27 | 배일주 | 암 치료를 위한 육산화사비소의 병용요법 |
KR101100786B1 (ko) | 2008-12-16 | 2011-12-29 | (주)천지산 | 암에 대한 방사선 치료 증진용 조성물 |
KR101391148B1 (ko) | 2012-03-29 | 2014-05-07 | 옥은희 | 면역 관련 질환 및 산화적 스트레스 관련 질환의 예방 또는 치료용 조성물 |
KR101755556B1 (ko) * | 2016-11-18 | 2017-07-07 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 뇌암 예방 또는 치료용 약학 조성물 및 이의 제조방법 |
-
2016
- 2016-11-21 KR KR1020160155228A patent/KR101834366B1/ko active IP Right Grant
-
2017
- 2017-01-24 CN CN202310553812.8A patent/CN116440161A/zh active Pending
- 2017-01-24 CN CN201710060429.3A patent/CN108079018A/zh active Pending
- 2017-11-17 CA CA3043153A patent/CA3043153C/en active Active
- 2017-11-17 WO PCT/KR2017/013148 patent/WO2018093215A1/ko active Application Filing
- 2017-11-17 JP JP2019547058A patent/JP6824432B2/ja active Active
- 2017-11-17 EP EP17872391.2A patent/EP3542803B1/en active Active
- 2017-11-17 AU AU2017360701A patent/AU2017360701B2/en active Active
- 2017-11-17 MX MX2019005736A patent/MX2019005736A/es unknown
- 2017-11-17 MY MYPI2019002665A patent/MY197198A/en unknown
- 2017-11-17 BR BR112019009483A patent/BR112019009483A2/pt unknown
- 2017-11-17 US US16/462,011 patent/US10525079B2/en active Active
-
2019
- 2019-04-25 ZA ZA201902612A patent/ZA201902612B/en unknown
- 2019-05-14 SA SA519401785A patent/SA519401785B1/ar unknown
- 2019-05-19 IL IL266706A patent/IL266706B/en unknown
- 2019-05-20 PH PH12019501119A patent/PH12019501119A1/en unknown
- 2019-05-20 CL CL2019001369A patent/CL2019001369A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN116440161A (zh) | 2023-07-18 |
EP3542803A4 (en) | 2020-07-15 |
EP3542803B1 (en) | 2022-12-21 |
JP2020503372A (ja) | 2020-01-30 |
US10525079B2 (en) | 2020-01-07 |
WO2018093215A1 (ko) | 2018-05-24 |
PH12019501119A1 (en) | 2019-11-25 |
MY197198A (en) | 2023-05-31 |
AU2017360701A1 (en) | 2019-06-20 |
ZA201902612B (en) | 2020-11-25 |
MX2019005736A (es) | 2019-07-04 |
US20190328780A1 (en) | 2019-10-31 |
EP3542803A1 (en) | 2019-09-25 |
IL266706A (en) | 2019-08-29 |
CA3043153A1 (en) | 2018-05-24 |
JP6824432B2 (ja) | 2021-02-03 |
BR112019009483A2 (pt) | 2019-07-30 |
SA519401785B1 (ar) | 2021-12-14 |
IL266706B (en) | 2022-02-01 |
CA3043153C (en) | 2021-11-02 |
AU2017360701B2 (en) | 2021-04-01 |
KR101834366B1 (ko) | 2018-03-05 |
CN108079018A (zh) | 2018-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019001369A1 (es) | Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo. | |
CL2019001565A1 (es) | Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico. | |
ECSP18094790A (es) | Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas | |
CL2019001344A1 (es) | Composición farmacéutica para prevenir o tratar el cáncer de cerebro incluyendo el polimorfo cristalino del hexoxido tetraarsenico y el método para preparar el mismo. | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
CL2018001230A1 (es) | Tratamiento de osteoartritis | |
DOP2017000261A (es) | Derivados de ciclohexano sustituido con amido | |
NI201700011A (es) | 2-(morfolin-4-il)-1,7-naftiridinas. | |
NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
CR20160518A (es) | Compuestos para tratar atrofia muscular espinal | |
ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
CL2015003491A1 (es) | Compuestos químicos. | |
SV2017005405A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
CL2019000266A1 (es) | Composición de cannabis. | |
CR20160564A (es) | Dinucleótidos cíclicos como moduladores de sting | |
TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
DOP2017000278A (es) | Piridinas sustituidas y método de uso | |
BR112016023558A2 (pt) | compostos úteis como imunomoduladores | |
ECSP18060342A (es) | Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos | |
UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
DOP2019000193A (es) | Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende | |
DOP2017000107A (es) | Diamino-quinoleina 2,4 sustituida como nuevos agentes anticancerigenos | |
CL2017001181A1 (es) | Amidas de morfolina y 1,4-oxazepano como agonistas del receptor de somatostatina subtipo 4(sstr4) | |
CO2017007076A2 (es) | Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo |